Royalty Report: Drugs, Disease, Therapeutic – Collection: 220120

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Disease
  • Therapeutic
  • Parkinsons Disease
  • Personal Care Products
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 220120

License Grant
Licensor grants to the Licensee of Israel the right to use certain clinical and safety data codeveloped by Licensor in connection with studies of CEP-1347 for the treatment of Parkinsons Disease.

Licensor grants the non-exclusive right under the Listed Patents to manufacture, use, market and sell Generic Modafinil Product in the United States and other markets, including provision of modafinil API for Subject Modafinil Product or finished drug which has modafinil as an active ingredient.

License Property
Modafinil Product shall mean all finished pharmaceutical products that contain the compound modafinil, including, without limitation, its salts, esters, enantiomers, isomers and polymorphs, including without limitation, PROVIGIL®, SPARLON® and NUVIGIL®, sold by Cephalon, its Affiliates, distributors and resellers.
Field of Use
This agreement is for the pharmaceutical industry, with specific applications for attention-deficit/hyperactivity disorder ADHD in children and adolescents, excessive sleepiness and Parkinsons Disease.

IPSCIO Record ID: 203304

License Grant
The Israeli Licensor grants a non-exclusive, worldwide license to all Intellectual Property Rights solely for the manufacture, development, formulation, use, sale, offer for sale, and importation of finished pharmaceutical products that contain the compound modafinil, including, without limitation, its salts, esters, enantiomers, isomers and polymorphs, including without limitation, any aspect of such rights which purport to cover or relate to PROVIGIL®, SPARLON® and/or NUVIGIL®]
License Property
Modafinil Product shall mean all finished pharmaceutical products that contain the compound modafinil, including, without limitation, its salts, esters, enantiomers, isomers and polymorphs, including without limitation, PROVIGIL®, SPARLON® and NUVIGIL®, sold by Licensee, its Affiliates, distributors and resellers.
Field of Use
This agreement is for the pharmaceutical industry, with specific applications for attention-deficit/hyperactivity disorder ADHD in children and adolescents, excessive sleepiness and Parkinsons Disease.

IPSCIO Record ID: 29182

License Grant
The French Licensor granted an exclusive License for the Licensed Products and/or Combination Products from the Compound, and to use and sell Licensed Products throughout the Territory.
License Property
Licensed Product shall mean any pharmaceutical specialty whether sold by prescription, over-the-counter, or otherwise containing the Compound.

Compound shall mean modafinil and/or any other similar compound, isomer or salt thereof.  Licensor has discovered and developed an original compound, modafinil (INN) for which it owns patent rights in the U.S.A., such compound being useful in the field of the central nervous system.  Modafinil compound is the active drug substance contained in Provigil.

Field of Use
Provigil is approved for use by those suffering from excessive daytime sleepiness associated with narcolepsy.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.